EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025
Rhea-AI Summary
EDAP TMS SA (NASDAQ: EDAP), a global leader in robotic energy-based therapies, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, before market open. The company will host a conference call and webcast at 8:30 AM EDT on the same day.
The earnings discussion will be led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch. Investors can join via phone using the domestic line (1-800-267-6316) or international line (1-203-518-9783) with passcode "EDAP", or through the webcast platform.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EDAP gained 1.42%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT
LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
Date: Thursday, May 15th
Time: 8:30 am EDT
Domestic: 1-800-267-6316
International: 1-203-518-9783
Passcode: EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1714475&tp_key=2c6b64f895
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
When will EDAP (NASDAQ: EDAP) report Q1 2025 earnings?
How can I join EDAP's Q1 2025 earnings call?
Who will lead EDAP's Q1 2025 earnings call?
What is EDAP's main business focus?
